CD200 is a new prognostic factor in multiple myeloma.

Jérôme Moreaux (1, 2) , Dirk Hose (3) , Thierry Rème (1, 2) , Eric Jourdan (4) , Michael Hundemer (3) , Eric Legouffe (5) , Philippe Moine (1) , Philippe Bourin (6) , Marion Moos (3) , Jill Corre (6) , Thomas Möhler (3) , John de Vos (1, 2) , Jean Francois Rossi (5) , Hartmut Goldschmidt (3, 7) , Bernard Klein (1, 2)

1 IRB - Institut de recherche en biothérapie
2 Immunopathologie des maladies tumorales et autoimmunes
3 Department of Internal Medicine V
4 Service de médecine interne B
5 UM1 Médecine - Université Montpellier 1 - UFR de Médecine
6 Laboratoire de Thérapie Cellulaire
7 National center of tumour diseases Heidelberg

Using Affymetrix microarrays, we identified the expression of the CD200 gene in multiple myeloma cells (MMCs) of 112 patients with newly diagnosed multiple myeloma (MM). The CD200 gene was either absent or present (Affymetrix call) in 22% and 78% of MMCs, respectively. The CD200 gene is not expressed in cells of the patients' bone marrow (BM). CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. Patients with CD200(absent) MMCs have an increased event-free survival (EFS; 24 months) compared with patients with CD200(present) MMCs (14 months), after high-dose therapy and stem cell transplantation. In a Cox proportional-hazard model, the absence or presence of CD200 expression in MMCs is predictive for EFS for patients independently of ISS stage or beta2M serum levels. Thus, CD200 is an independent prognosis factor for patients with MM that could represent a new therapeutic target in MM.

Domaines: Cancer

Jérôme Moreaux, Dirk Hose, Thierry Rème, Eric Jourdan, Michael Hundemer, et al.. CD200 is a new prognostic factor in multiple myeloma.. Blood, 2006, 108 (13), pp.4194-7. ⟨10.1182/blood-2006-06-029355⟩. ⟨inserm-00130595⟩